14
H index
14
i10 index
734
Citations
Margaret K. Kyle : Citation Profile
Mines Paris | RESEARCH PRODUCTION: 19 Articles 57 Papers 6 Chapters RESEARCH ACTIVITY:
MORE DETAILS IN: ABOUT THIS REPORT:
|
25 years (2000 - 2025). Relations with other researchers
Works with: Authors registered in RePEc who have co-authored more than one work in the last five years with Margaret K. Kyle. | Is cited by:
| Cites to:
|
Main data
Where Margaret K. Kyle has published?
| Journals with more than one article published | # docs |
|---|---|
| Review of Industrial Organization | 2 |
| The Review of Economics and Statistics | 2 |
| Working Papers Series with more than one paper published | # docs |
|---|---|
| Post-Print / HAL | 26 |
| Working Papers / HAL | 10 |
| NBER Working Papers / National Bureau of Economic Research, Inc | 7 |
| CEPR Discussion Papers / C.E.P.R. Discussion Papers | 5 |
| SciencePo Working papers Main / HAL | 4 |
| TSE Working Papers / Toulouse School of Economics (TSE) | 2 |
Recent works citing Margaret K. Kyle (2025 and 2024)
| Year | Title of citing document |
|---|---|
| 2024 | The Linder hypothesis for foreign direct investment revisited. (2024). Steinbach, Sandro ; Kim, Dongin. In: Review of International Economics. RePEc:bla:reviec:v:32:y:2024:i:4:p:1901-1928. Full description at Econpapers || Download paper |
| 2024 | Do Deep Trade Agreements with Intellectual Property Provisions Actually Increase International Trade?. (2024). Kanwar, Sunil ; Ah, Ridwan. In: Working papers. RePEc:cde:cdewps:344. Full description at Econpapers || Download paper |
| 2024 | Revisiting the Impact of TRIPS on IPR-intensive Export Flows: Evidence from Staggered Difference-in-Differences. (2024). Kanwar, Sunil ; Ah, Ridwan. In: Working papers. RePEc:cde:cdewps:351. Full description at Econpapers || Download paper |
| 2024 | A toolkit for setting and evaluating price floors. (2024). Hernández, Carlos Eduardo ; Cantillo-Cleves, Santiago. In: University of California at San Diego, Economics Working Paper Series. RePEc:cdl:ucsdec:qt0209r817. Full description at Econpapers || Download paper |
| 2025 | Foreign Market Access’ Role for Export Quality. (2025). Hillrichs, Dorothee. In: CESifo Working Paper Series. RePEc:ces:ceswps:_11906. Full description at Econpapers || Download paper |
| 2024 | Acquiring R&D Projects: Who, When, and What? Evidence from Antidiabetic Drug Development. (2024). Seldeslachts, Jo ; veugelers, reinhilde ; Newham, Melissa ; Malek, Jan. In: Discussion Papers of DIW Berlin. RePEc:diw:diwwpp:dp2073. Full description at Econpapers || Download paper |
| 2025 | Global public goods, fiscal policy coordination, and welfare in the world economy. (2025). Agénor, Pierre-Richard ; Agnor, Pierre-Richard ; Pereira, Luiz A. In: European Economic Review. RePEc:eee:eecrev:v:172:y:2025:i:c:s0014292124002435. Full description at Econpapers || Download paper |
| 2025 | Hydrogen fuel cell technology development in China: Technology evolution, city-cluster network and industry chain distribution. (2025). Zhou, Peng ; Zhang, Hongyan ; Fan, Li-Wei ; Wang, Xue. In: Energy. RePEc:eee:energy:v:322:y:2025:i:c:s0360544225012484. Full description at Econpapers || Download paper |
| 2024 | Buying winners. (2024). Louis-Sidois, Charles. In: Games and Economic Behavior. RePEc:eee:gamebe:v:143:y:2024:i:c:p:1-11. Full description at Econpapers || Download paper |
| 2024 | The impact of changing the reference countries on the list prices for patented medicines in Canada: A policy analysis. (2024). Hollis, Aidan ; Zhang, Wei ; Grootendorst, Paul ; Guh, Daphne P ; Anis, Aslam H. In: Health Policy. RePEc:eee:hepoli:v:144:y:2024:i:c:s0168851024000745. Full description at Econpapers || Download paper |
| 2024 | Branded response to generic entry: Detailing beyond the patent cliff. (2024). Hariharan, Vijay Ganesh ; Landsman, Vardit ; Stremersch, Stefan. In: International Journal of Research in Marketing. RePEc:eee:ijrema:v:41:y:2024:i:3:p:567-588. Full description at Econpapers || Download paper |
| 2025 | A many-location home market effect and a home biased geography. (2025). Norris, Jordan. In: Journal of International Economics. RePEc:eee:inecon:v:154:y:2025:i:c:s0022199625000133. Full description at Econpapers || Download paper |
| 2024 | Do firms with technological capabilities rush in? Evidence from the timing of licensing of Stanford inventions. (2024). Kim, Young-Choon ; Kotha, Reddi ; Rhee, Mooweon. In: Journal of Business Research. RePEc:eee:jbrese:v:178:y:2024:i:c:s0148296324001838. Full description at Econpapers || Download paper |
| 2024 | Regulating ethical experimentation: Impacts of the breakthrough therapy designation on drug R&D. (2024). Hermosilla, Manuel. In: Journal of Health Economics. RePEc:eee:jhecon:v:94:y:2024:i:c:s0167629623001327. Full description at Econpapers || Download paper |
| 2024 | A toolkit for setting and evaluating price floors. (2024). Hernández, Carlos Eduardo ; Cantillo-Cleves, Santiago. In: Journal of Public Economics. RePEc:eee:pubeco:v:232:y:2024:i:c:s0047272724000203. Full description at Econpapers || Download paper |
| 2024 | Stronger Patent Regime, Innovation and Scientist Mobility. (2024). Ganguly, Madhuparna. In: Research in Economics. RePEc:eee:reecon:v:78:y:2024:i:4:s1090944324000681. Full description at Econpapers || Download paper |
| 2024 | The missing middle: Value capture in the market for startups. (2024). Arora, Ashish ; Ronde, Thomas ; Fosfuri, Andrea. In: Research Policy. RePEc:eee:respol:v:53:y:2024:i:3:s0048733324000076. Full description at Econpapers || Download paper |
| 2024 | Market size, trade, and productivity reconsidered: poverty traps and the home market effect. (2024). Berliant, Marcus ; Tabuchi, Takatoshi. In: MPRA Paper. RePEc:pra:mprapa:121619. Full description at Econpapers || Download paper |
| 2024 | Market size, trade, and productivity reconsidered: poverty traps and the home market effect. (2024). Berliant, Marcus ; Tabuchi, Takatoshi. In: MPRA Paper. RePEc:pra:mprapa:122854. Full description at Econpapers || Download paper |
| 2025 | Market size, trade, and productivity reconsidered: poverty traps and the home market effect. (2025). Berliant, Marcus ; Tabuchi, Takatoshi. In: Economic Theory Bulletin. RePEc:spr:etbull:v:13:y:2025:i:1:d:10.1007_s40505-024-00283-9. Full description at Econpapers || Download paper |
| 2024 | The design of external reference pricing schemes and the choice of reference countries and pricing rules. (2024). Birg, Laura. In: Canadian Journal of Economics/Revue canadienne d'économique. RePEc:wly:canjec:v:57:y:2024:i:4:p:1182-1202. Full description at Econpapers || Download paper |
| 2024 | Harmonizing regulatory market approval of products with high safety requirements: Evidence from the European pharmaceutical market. (2024). Stargardt, Tom ; Grunwald, Fabian. In: Health Economics. RePEc:wly:hlthec:v:33:y:2024:i:7:p:1546-1564. Full description at Econpapers || Download paper |
| 2025 | Effect of vaccine recommendations on consumer and firm behavior. (2025). Lawler, Emily C ; Henkhaus, Laura E ; Churchill, Brandyn F. In: Journal of Policy Analysis and Management. RePEc:wly:jpamgt:v:44:y:2025:i:1:p:125-150. Full description at Econpapers || Download paper |
| 2024 | Effects of intellectual property rights protection on services export diversification in developing countries. (2024). Gnangnon, Sena Kimm. In: KDI Journal of Economic Policy. RePEc:zbw:kdijep:289788. Full description at Econpapers || Download paper |
Works by Margaret K. Kyle:
| Year | Title | Type | Cited |
|---|---|---|---|
| 2005 | Public & Private Spillovers: Location and the Productivity of Pharmaceutical Research In: Annals of Economics and Statistics. [Full Text][Citation analysis] | article | 59 |
| 2006 | Public & Private Spillovers, Location and the Productivity of Pharmaceutical Research.(2006) In: NBER Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 59 | paper | |
| 2017 | Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs In: American Economic Review. [Full Text][Citation analysis] | article | 4 |
| 2016 | Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs.(2016) In: Post-Print. [Citation analysis] This paper has nother version. Agregated cites: 4 | paper | |
| 2017 | Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs.(2017) In: Post-Print. [Citation analysis] This paper has nother version. Agregated cites: 4 | paper | |
| 2017 | Is American Health Care Uniquely Inefficient? Evidence from Prescription Drugs.(2017) In: NBER Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 4 | paper | |
| 2025 | Lessons for the United States from Pharmaceutical Regulation Abroad In: Journal of Economic Perspectives. [Full Text][Citation analysis] | article | 0 |
| 2013 | Intellectual Property Protection and the Geography of Trade In: Journal of Industrial Economics. [Full Text][Citation analysis] | article | 52 |
| 2006 | The role of firm characteristics in pharmaceutical product launches In: RAND Journal of Economics. [Full Text][Citation analysis] | article | 46 |
| 2011 | Strategic Responses to Parallel Trade In: The B.E. Journal of Economic Analysis & Policy. [Full Text][Citation analysis] | article | 50 |
| 2007 | Strategic Responses to Parallel Trade.(2007) In: NBER Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 50 | paper | |
| 2016 | The Effects of Pharmaceutical Innovation on Cancer Mortality In: CEPR Discussion Papers. [Full Text][Citation analysis] | paper | 1 |
| 2017 | Strategic Interaction Among Governments in the Provision of a Global Public Good In: CEPR Discussion Papers. [Full Text][Citation analysis] | paper | 6 |
| 2017 | Strategic interaction among governments in the provision of a global public good.(2017) In: Journal of Public Economics. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 6 | article | |
| 2017 | Strategic interaction among governments in the provision of a global public good.(2017) In: Post-Print. [Citation analysis] This paper has nother version. Agregated cites: 6 | paper | |
| 2017 | Strategic interaction among governments in the provision of a global public good.(2017) In: Post-Print. [Citation analysis] This paper has nother version. Agregated cites: 6 | paper | |
| 2017 | Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets In: CEPR Discussion Papers. [Full Text][Citation analysis] | paper | 3 |
| 2018 | Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets.(2018) In: Post-Print. [Citation analysis] This paper has nother version. Agregated cites: 3 | paper | |
| 2016 | Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets.(2016) In: Working Papers. [Citation analysis] This paper has nother version. Agregated cites: 3 | paper | |
| 2017 | Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets.(2017) In: Working Papers. [Citation analysis] This paper has nother version. Agregated cites: 3 | paper | |
| 2018 | Are Important Innovations Rewarded? Evidence from Pharmaceutical Markets.(2018) In: Review of Industrial Organization. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 3 | article | |
| 2011 | Inefficiencies in technology transfer: theory and empirics In: CEPR Discussion Papers. [Full Text][Citation analysis] | paper | 3 |
| 2011 | Inefficiencies in technology transfer: theory and empirics.(2011) In: SciencePo Working papers Main. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 3 | paper | |
| 2011 | Inefficiencies in technology transfer: theory and empirics.(2011) In: Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 3 | paper | |
| 2011 | Investments in Pharmaceuticals Before and After TRIPS In: CEPR Discussion Papers. [Full Text][Citation analysis] | paper | 74 |
| 2009 | Investments in Pharmaceuticals Before and After TRIPS.(2009) In: NBER Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 74 | paper | |
| 2012 | Investments in Pharmaceuticals Before and After TRIPS.(2012) In: The Review of Economics and Statistics. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 74 | article | |
| 2011 | Markets for Pharmaceutical Products11The authors thank Tom McGuire for editorial advice and improvements and participants at the Handbook conference for helpful suggestions. In: Handbook of Health Economics. [Full Text][Citation analysis] | chapter | 0 |
| 2022 | Incentives for pharmaceutical innovation: What’s working, what’s lacking In: International Journal of Industrial Organization. [Full Text][Citation analysis] | article | 0 |
| 2022 | Incentives for pharmaceutical innovation: What’s working, what’s lacking.(2022) In: Post-Print. [Citation analysis] This paper has nother version. Agregated cites: 0 | paper | |
| 2008 | Mergers and Alliances in Pharmaceuticals: Effects on Innovation and R&D Productivity In: Chapters. [Full Text][Citation analysis] | chapter | 3 |
| 2006 | Objective and self‐report work performance measures: a comparative analysis In: International Journal of Productivity and Performance Management. [Full Text][Citation analysis] | article | 0 |
| 2004 | Does locale affect R&D productivity? the case of pharmaceuticals In: FRBSF Economic Letter. [Full Text][Citation analysis] | article | 0 |
| 2000 | Did U.S. bank supervisors get tougher during the credit crunch? Did they get easier during the banking boom? Did it matter to bank lending? In: Finance and Economics Discussion Series. [Full Text][Citation analysis] | paper | 46 |
| 2001 | Did US Bank Supervisors Get Tougher during the Credit Crunch? Did They Get Easier during the Banking Boom? Did It Matter to Bank Lending?.(2001) In: NBER Chapters. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 46 | chapter | |
| 2000 | Did U.S. Bank Supervisors Get Tougher During the Credit Crunch? Did They Get Easier During the Banking Boom? Did It Matter to Bank Lending?.(2000) In: NBER Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 46 | paper | |
| 2016 | Competition Law, Intellectual Property, and the Pharmaceutical Sector In: Post-Print. [Citation analysis] | paper | 6 |
| 2016 | Competition law, intellectual property, and the pharmaceutical sector.(2016) In: Post-Print. [Citation analysis] This paper has nother version. Agregated cites: 6 | paper | |
| 2016 | Study for European Commission (DG Internal Market, Industry, Entrepreneurship and SMEs) on supplementary patent certificates In: Post-Print. [Citation analysis] | paper | 0 |
| 2016 | Estimating the Benefits of Cancer Treatments In: Post-Print. [Citation analysis] | paper | 0 |
| 2019 | The Single Market in Pharmaceuticals In: Post-Print. [Citation analysis] | paper | 2 |
| 2019 | The Single Market in Pharmaceuticals.(2019) In: Review of Industrial Organization. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 2 | article | |
| 2019 | Productivity and competitiveness in the euro area: A view from France In: Post-Print. [Citation analysis] | paper | 1 |
| 2019 | Productivity and competitiveness in the euro area: A view from France.(2019) In: SciencePo Working papers Main. [Citation analysis] This paper has nother version. Agregated cites: 1 | paper | |
| 2019 | The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals In: Post-Print. [Citation analysis] | paper | 2 |
| 2020 | The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals.(2020) In: Post-Print. [Citation analysis] This paper has nother version. Agregated cites: 2 | paper | |
| 2019 | The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals.(2019) In: NBER Chapters. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 2 | chapter | |
| 2020 | The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals.(2020) In: Innovation Policy and the Economy. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 2 | article | |
| 2021 | Innovation pharmaceutique : comment combler le retard français ? In: Post-Print. [Full Text][Citation analysis] | paper | 0 |
| 2021 | Do Patents Work? Evidence from Pharmaceutical Innovation In: Post-Print. [Citation analysis] | paper | 0 |
| 2016 | Competition and the Efficiency of Markets for Technology In: Post-Print. [Citation analysis] | paper | 21 |
| 2016 | Competition and the Efficiency of Markets for Technology.(2016) In: SciencePo Working papers Main. [Citation analysis] This paper has nother version. Agregated cites: 21 | paper | |
| 2013 | Competition and the Efficiency of Markets for Technology.(2013) In: IDEI Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 21 | paper | |
| 2016 | Competition and the Efficiency of Markets for Technology.(2016) In: Management Science. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 21 | article | |
| 2013 | Competition and the Efficiency of Markets for Technology.(2013) In: TSE Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 21 | paper | |
| 2022 | “Economic Issues in Assessing Potential and Nascent Competition” In: Post-Print. [Citation analysis] | paper | 0 |
| 2022 | Intersection of Intellectual Property and Competition Policy in Recent Cases In: Post-Print. [Citation analysis] | paper | 0 |
| 2022 | COVID-19 and clinical trials In: Post-Print. [Citation analysis] | paper | 0 |
| 2019 | The More We Die, The More We Sell? A Simple Test of the Home-Market Effect* In: Post-Print. [Citation analysis] | paper | 53 |
| 2016 | The More We Die, The More We Sell? A Simple Test of the Home-Market Effect.(2016) In: Working Papers. [Citation analysis] This paper has nother version. Agregated cites: 53 | paper | |
| 2016 | The More We Die, The More We Sell? A Simple Test of the Home-Market Effect.(2016) In: NBER Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 53 | paper | |
| 2019 | The More We Die, The More We Sell? A Simple Test of the Home-Market Effect.(2019) In: The Quarterly Journal of Economics. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 53 | article | |
| 2023 | The economics of new product launches and access to pharmaceutical products in the EU: A perspective on the EC’s proposed reform of the EU pharmaceutical legislation In: Post-Print. [Full Text][Citation analysis] | paper | 0 |
| 2024 | Hot tub time machine? What role for Towercast in EU merger control In: Post-Print. [Citation analysis] | paper | 0 |
| 2011 | Evolving Brand-Name And Generic Drug Competition May Warrant A Revision Of The Hatch-Waxman Act In: Post-Print. [Citation analysis] | paper | 1 |
| 2012 | Evolution of Market Exclusivity, Paragraph IV Challenges and Generic Penetration In: Post-Print. [Citation analysis] | paper | 0 |
| 2012 | Assessing the population health impact of market interventions to improve access to antiretroviral treatment In: Post-Print. [Citation analysis] | paper | 0 |
| 2011 | Inefficiencies in the sale of ideas: theory and empirics In: SciencePo Working papers Main. [Full Text][Citation analysis] | paper | 1 |
| 2011 | Inefficiencies in the sale of ideas: theory and empirics.(2011) In: Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 1 | paper | |
| 2016 | Government Free-riding in Research Funding In: Working Papers. [Citation analysis] | paper | 0 |
| 2016 | Estimating the Benefits of Innovation In: Working Papers. [Citation analysis] | paper | 0 |
| 2016 | Intellectual Property Rights and Access to Innovation: Evidence from TRIPS In: Working Papers. [Citation analysis] | paper | 18 |
| 2014 | Intellectual property rights and access to innovation: evidence from TRIPS.(2014) In: Working Papers. [Citation analysis] This paper has nother version. Agregated cites: 18 | paper | |
| 2014 | Intellectual Property Rights and Access to Innovation: Evidence from TRIPS.(2014) In: NBER Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 18 | paper | |
| 2017 | Korean pharmaceutical industry policy: lessons for Korea In: Working Papers. [Citation analysis] | paper | 0 |
| 2010 | Public and Private Spillovers: Location and the Productivity of Pharmaceutical Research In: NBER Chapters. [Citation analysis] | chapter | 17 |
| 2003 | The Long Shadow of Patent Expiration. Generic Entry and Rx-to-OTC Switches In: NBER Chapters. [Full Text][Citation analysis] | chapter | 30 |
| 2011 | Inefficiencies in technology transfer: theory and empirics In: Sciences Po publications. [Full Text][Citation analysis] | paper | 4 |
| 2007 | Pharmaceutical Price Controls and Entry Strategies In: The Review of Economics and Statistics. [Full Text][Citation analysis] | article | 141 |
| 2016 | The Effects of Pharmaceutical Innovation on Cancer Mortality Rates In: TSE Working Papers. [Full Text][Citation analysis] | paper | 1 |
| 2002 | Deregulating Direct-to-Consumer Marketing of Prescription Drugs: Effects on Prescription and Over-the-Counter Product Sales In: Journal of Law and Economics. [Full Text][Citation analysis] | article | 35 |
| 2007 | Generic competition and market exclusivity periods in pharmaceuticals In: Managerial and Decision Economics. [Full Text][Citation analysis] | article | 54 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated July, 2 2025. Contact: CitEc Team